CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
Go back to CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026| (NASDAQ: CRSP) | Delayed: 54.69 -1.1 (1.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.79 | 52 Week High | $18.88 | |||
| Open | $54.45 | 52 Week Low | $13.75 | |||
| Day High | $54.88 | P/E | N/A | |||
| Day Low | $52.78 | EPS | $0.00 | |||
| Volume | 734,098 | |||||
